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Abstract 
Purpose: To examine the role of endogenous nitric oxide (NO•) and influence of p53 status during 
apoptosis induced by a selective iNOS inhibitor, N-[(3-aminomethyl) benzyl] acetamidine (1400W), 
and/or an NO• scavenger carboxy-PTIO (c-PTIO) in two isogenic human melanoma cell lines, wild-type 
p53 (A375) and p53 mutant (SK mel-28) cells.  
Methods: 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) and Annexin V/propidium 
iodide assay were used to test for antiproliferation and apoptosis, respectively. Griess and reverse 
transcription-polymerase chain reaction (RT-PCR) reactions were carried out to assay NO• production 
and the mRNA levels of inhibitors of apoptosis (IAP).  
Results: c-PTIO and 1400W, alone or in combination, inhibited cell growth and promoted apoptosis via 
sub-G1 cell cycle arrest mediated by decrease in NO•. Apoptosis was delayed and greatly reduced in 
magnitude in SK mel-28 cells, underscoring the importance of p53 modulation of the response. In both 
cell types, apoptosis induced by iNOS inhibition and/or NO• depletion was blocked by an exogenous 
NO• donor, sodium nitroprusside. It was also found that inhibitors of apoptosis family (survivin, XIAP and 
cIAP1) were significantly depressed, which appear to play an important role in the regulation of p53-
mediated apoptotic response under these conditions.  
Conclusion: The data obtained provide insight into the mechanism of cell proliferation action of 
endogenous NO•, based on p53 status, and indicate manipulation of iNOS may offer exciting 
opportunities to improve the effectiveness of melanoma treatment.  
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Melanoma is the most devastating skin cancer 
with the highest increase in incidence in recent 
years [1]. Melanoma originates from a malignant 
degenerated melanocyte, which is a highly 
aggressive tumor cell with poor rates of survival 
once it has metastasized. Melanoma is 
intrinsically resistant to treatments such as 
radiation and conventional chemotherapy, for 
possible reasons that involve drug-detoxifying 
properties of melanosomes [2], energy 
dependent drug efflux pumps [3], overexpression 
of inhibitors of apoptosis [4], altered expression 
of oncogenes or tumor suppressors [4] and 
endogenous nitric oxide (NO•) [5]. Evidently, 
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investigating the leading drug resistant 
mechanisms and how to reverse or circumvent 
them would be critical steps in developing 
effective new therapies for melanoma patients. 
 
NO• produced naturally by NO• synthase (NOS) 
enzymes plays a role in many different 
physiological processes, including vasodilation, 
neurotransmission, antimicrobial action, 
inflammation and cancer [6]. The NO• released 
by the constitutive enzymes neuronal NOS 
(nNOS) and endothelial NOS (eNOS) acts as an 
important signaling molecule in the 
cardiovascular and nervous systems [6] and NO• 
released by the inducible NOS (iNOS) is 
generated for long periods, by cells of the 
immune system among others, and has been 
shown to be principally involved in inflammatory 
processes and cancer formation [6].  
 
The role for NO• in tumor biology is multi-
dimensional. High level of NO• has been 
proposed to be cytotoxic for cancer cells. By 
contrast, at low level, constitutive production of 
endogenous NO• can promote tumor growth by 
inducing anti-apoptotic effects in many tumor 
types including melanoma [7]. Whether iNOS-
derived NO• has any positive or negative effect 
on tumor progression, however, is still poorly 
understood. Numerous reports have suggested 
that growth and metastasis of solid tumors such 
as oral squamous cell carcinoma [8], breast 
cancer [9], melanoma [10], colon cancer [11] and 
gynecological malignancies [12] is correlated 
with an enhanced expression of iNOS. On the 
other hand, it has been reported that 
overexpression of iNOS gene can suppress 
tumor survival and metastasis of melanoma [13] 
and renal carcinoma cells [14]. From these 
paradoxical reports, iNOS seems to be related to 
anticancer as well as carcinogenesis.  
 
The aim of the present study was to assess the 
inhibitory effects of endogenous NO• on the 
proliferation of human melanoma cells by 
employing a selective iNOS inhibitor 1400W, an 
NO• scavenger carboxy-PTIO (c-PTIO) and an 
NO• donor sodium nitroprusside (SNP) for 
modulating NO• consumption. The mechanisms 
of apoptotic cell death and the role of IAP family 




Cell cultures and chemicals  
 
The choice of human tumor cells was based on 
p53 status. The cell line (both were a gift from Dr. 
G. N. Wogan, Massachusetts Institute of 
Technology) used were human melanoma A375 
(p53 wild-type) and SK mel-28 (p53 mutant, point 
mutation in codon 145 of p53) cells. The cells 
were grown in high glucose Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10 
% heat-inactivated fetal bovine serum (FBS), 100 
units/ml penicillin, 100 μg/ml streptomycin and 2 
mM L-glutamine at 37 ºC in 5 % CO2 and 
cultured every few days to maintain exponential 
growth. Reagents and cell culture materials were 
purchased from the following sources: cell 
culture materials, Lonza (Walkersville, MD, US); 
Fetal Bovine Serum (FBS), PAA Laboratories 
(Coelbe, Germany); 1400W dihydrochloride, 2-
(4-Carboxyphenyl)-4,4,5,5-
tetramethylimidazoline-1-oxyl-3-oxide (c-PTIO) 
and sodium nitroprusside (SNP), Sigma 
Chemical (St. Louis, MO, USA); N-methyl-L-
arginine monoacetate (NMA) and cisplatin, 
CalBiochem (Salt Lake City, UT, USA).  
 
Cell viability assay  
 
The number of viable cells was estimated by 
measurement of the rate of mitochondrial 
metabolism of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) using a cell 
proliferation kit I (Roche, Indianapolis, IN, USA) 
according to the manufacturer’s instructions. 
Briefly, cells were plated at 5 × 104 cells/well in 
100 μL volume in 96-well plates and were then 
grown for 24 h in DMEM supplemented with 10 
% FBS. Different concentrations of test drugs or 
DMSO 0.1 % were added to the wells for the 
designated time points.  
 
Cells were then incubated with 10 μL of MTT (5 
mg/ml) at 37 ºC in the dark for 4 h. The 
tetrazolium crystals were solubilized by the 
addition of 100 μL of 10 % SDS in 0.01 N HCl. 
After overnight incubation at 37 ºC, the 
absorbance was measured at 550 nm using a 
Packard EL340 microplate reader (Bio-Tek 
Instruments, Winooski, VT, US). The relative 
percentage of cell survival was calculated by 
dividing the absorbance of treated cells by that of 
the control in each experiment. Results from the 
MTT assay have been used to derive the 50 % 
effective concentrations (EC50) of each drug to 
induce growth inhibition. 
 
Apoptosis analysis  
 
Apoptosis after treatment was quantitatively 
evaluated with a Becton Dickinson FACScan 
equipped with CellQuest software following 
annexin V-FITC and propidium iodide staining 
(Clontech Laboratories, Palo Alto, CA) following 
procedures reported previously [11]. 
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Cell cycle analysis  
 
Cells were seeded in 100-mm tissue culture 
dishes at a density of 2 × 106 cells/ml and were 
treated with 1400W and/or c-PTIO in the 
presence or absence of SNP for 72 h. The cells 
were harvested, washed twice in PBS and fixed 
in 70 % cold ethanol overnight. They were then 
suspended in 1 % BSA (bovine serum albumin)-
PBS solution containing 500 μg/ml propidium 
iodide and 10 μg/ml RNase, incubated at 37 °C 
for 30 min and analyzed with a Becton Dickinson 
FACScan (BD Bioscience, San Jose, CA, USA). 
Cell fit analysis determined the percentage of 
cells in a specific stage of the cell cycle using 
CellQuest software, and expressed as a 
percentage of cells in the respective phases. 
 
DNA fragmentation analysis  
 
Isolation of DNA and analysis by agarose gel 
electrophoresis were done using a GenEluteTM 
mammalian genomic DNA miniprep kit (Sigma) 
as described [11]. Isolated DNA was suspended 
in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 
9.0) and quantified by absorbance at 260 nm. 
Fragmented DNA was loaded onto 1.8 % 
agarose gel containing 1 × TBE buffer and 
separated by electrophoresis for 2 h at 50 V, 
then photographed after staining with 0.5 ng/ml 
ethidium bromide. 
 
Measurement of nitrite production  
 
NO•, resulting from NOS, reacts rapidly with O2 
and accumulates in the culture medium as nitrite 
and nitrate. NO• production was assessed by 
measuring nitrite in media fractions by the Griess 
reaction as previously described [15]. Optical 
density was measured using a microplate reader 
at 540 nm, with fresh culture media serving as 
the blank. Determinations were performed in 
triplicate. The values were obtained by 
comparison with standard concentrations of 
sodium nitrite and expressed as pmoles per 106 
viable (trypan blue-excluding) cells. 
 
Semiquantitative RT-PCR analysis  
 
Total RNA was extracted using the Tri Reagent 
kit from Sigma and semiquantitative RT-PCR 
analysis was performed using the TOP script™ 
one-step RT PCR kit (Enzynomics, Daejeon, 
Korea) following the manufacturer’s 
recommended protocol. Two µg total RNA were 
used in each reaction. Primer sequences were 
as follows : for nNOS, sense 5ʹ-
TTGGGGGCCTGGGATTTCTGG-3ʹ, antisense, 
5ʹ-GTTGGCATGGGGGAGTGAGC-3ʹ; for iNOS, 
sense 5ʹ-CCAGTGACACAGGATGACCTTCAG-
3ʹ, antisense 5ʹ-TGCCATTGTTGGTGGAGTAAC 
G-3¬ʹ; for eNOS, sense 5ʹ-CCAGCTAGCCAA 
AGTCACCAT-3¬ʹ, antisense 5ʹ-GTCTCGGAGC 
CATACAGGATT-3¬ʹ; for survivin, sense 5ʹ-
GCATGGGTGCCCCGACGTTG-3¬ʹ, antisense 
5ʹ-GCTCCGGCCAGAGGCCTCAA-3¬ʹ; for XIAP, 
sense 5ʹ-ACACCATATACCCGAGGAAC-3¬ʹ, 
antisense 5ʹ-CTTGCATACTGTCTTTCTGA 
GC3¬ʹ; for cIAP-1, sense 5ʹ-AAGTTCCTAC 
CCCTGTCCAATG-3¬ʹ, antisense 5ʹ-CAAGTAGA 
TGAGGGTAACTGGC-3¬ʹ; for cIAP-2, sense 5ʹ-
CCTGTGGTTAAATCTGCCTTG-3¬ʹ, antisense 
5ʹ-CAATTCGGCACCATAACTCTG-3¬ʹ; for β-
actin, sense 5′-GGTCATCTTCTCGCGGTTGG 
CCTTGGGGT-3′, antisense 5′-CCCCAGGC 
ACCAGGGCGTGAT-3′. Amplified DNA was 
electrophoresed on 1.5% agarose gels and 
visualized by ethidium bromide staining. 
 
Statistical analysis  
 
Where necessary, statistical analysis was done 
by two-tailed Student’s t-test or one-way analysis 
of variance (ANOVA). Values of p < 0.05 were 




Effect of NO• on melanoma proliferation  
 
A375 cells treated with an NO• scavenger c-PTIO 
(0.1, 0.2 and 0.4 mM), a specific iNOS inhibitor 
1400W (1, 2 and 4 mM) and the nonspecific 
inhibitor of NOS NMA (1, 2 and 4 mM) for 48 h 
responded with respect to viability, in that all 
treatments decreased the percentage of viable 
cells dose-dependently (Figure 1A). The median 
effective concentration (EC50) with c-PTIO, 
1400W and NMA to cause cell growth inhibition 
was found to be 0.12, 2.04 and 4.05 mM, 
respectively (Figure 1A). We subsequently 
investigated the time-course of responses to 0.4 
mM c-PTIO, 4 mM 1400W and 4 mM NMA, in 
A375 and SK mel-28 cells treated for 24, 48 and 
72 h. Treatment of both cells with NOS inhibitors 
and NO• scavenger caused a time-dependent 
decrease in cell proliferation (Figures 1B and C). 
In comparison to A375 (p53 wild-type) cells, SK 
mel-28 (p53 mutant) cells were resistant to NO• 
modulators-induced cell death (Figures 1B and 
C). 
 
Nitrite production was measured in culture media 
following treatment for 72 h. Significant levels of 
nitrite were detected in the culture medium of 
A375 and SK mel-28 cells (Figure 1D). Cells 
treated with 4 mM 1400W and/or 400 μM c-PTIO 
for 72 h showed 1.3- to 2.8-fold decreases in 
nitrite level, as compared with untreated controls. 
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p53 wild-type A375 cells produced NO• at higher 
concentrations than p53 mutant SK mel-28 cells 
(Figure 1D); for example, the nitrite level in p53-
WT cells (1.7 pmoles/106 cells) was thrice that of 
p53-null cells (5 pmoles/106 cells) after 72 h of 
400 μM c-PTIO treatment. 
 
NO• reduces loss of viability induced by 
cisplatin  
 
To evaluate the role of endogenous NO• in 
melanoma cell survival, we determined the 
proliferation of A375 cells at 48 h by the addition 
of various concentration of the NO• donor SNP. 
As shown in Figure 2A, A375 cell proliferation 
was slightly increased by SNP at concentrations 
of 0.1-100 μM. Treatment of cells with more than 
100 μM SNP caused a dose-dependent 
decrease in cell viability (p < 0.05).  
 
Next, to verify whether endogenous NO• 
modulation regulates growth inhibition after 
cisplatin treatment; we incubated cells with 
cisplatin alone or in combination with 1400W and 
c-PTIO (Figure 2B). Cisplatin (cis-
diamminedichloroplatinum(ll)), the drug of choice 
for the treatment of tumors, selectively and 
persistently inhibits the synthesis of DNA and 
RNA [16]. 
 
Figure 1: Cell viability and intracellular nitrite level of A375 and SK mel-28 cells after NOS inhibition by NMA and 
1400W, or NO• scavenging by c-PTIO. A375 cells were treated with the various concentrations of NO• modulators 
for 48 h (A). A375 (B) and SK mel-28 (C) cells were incubated at indicated concentrations of NO• modulators 
(box) for 24, 48 and 72 h. The EC50 values (the effective concentration of the NO• modulators that reduced cell 
survival by 50%) were determined by the MTT assay. A375 and SK mel-28 cells were treated with 1400W (4 mM) 
or c-PTIO (400 μM) alone, or combination (4 mM of 1400W pre-incubated with 200 μM of c-PTIO for 24 h) (D). 
Results are presented as a percentage of control cells (mean ± SD, n=3). *p < 0.05 versus control 
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In this study, cell viability significantly decreased 
by 78 and 93 % after cisplatin treatment in A375 
and SK mel-28 cells, respectively (p < 0.05). 
When cells were co-incubated with both cisplatin 
and NO• modulators, viability significantly 
decreased by 3-folds over that which was 
induced by cisplatin alone in both cells (p < 
0.05). Moreover, the concomitant addition of 
SNP, a NO• donor, with NO• modulators caused 
cell re-growth, which indicates that the 
antiproliferative effect was specific to 
endogenous NO• depletion (p < 0.05) (Figure 
2B). 
 
Apoptosis identified by flow cytometric 
analysis  
 
To investigate the potential role of NO• in 
apoptosis regulation, A375 and SK mel-28 cells 
were treated with NO• modulators and donors 
SNP. Figure 3 shows that the iNOS inhibitor 
1400W and/or the NO• scavenger c-PTIO 
effectively increased the cellular response to cell 
death, whereas those co-treated with the NO• 
donor SNP had an opposite effect. A stronger 
apoptotic response was induced in A375 (p53 
wild-type) cells than in SK mel-28 (p53 mutant) 
cells (Figure 3). Approximately 71-74 and 40-70 
% of A375 and SK mel-28 cells (19- and 8-fold 
over control level), respectively, were apoptotic 
after treatment with 1400W and/or c-PTIO 
(Figure 3). 
 
Cell cycle distribution  
 
By FACS analysis of cell DNA content, there was 
a remarkable accumulation of subploid cells, 
sub-G1 peak, in A375 and SK mel-28 cells after 
treatment with NO• modulators alone or in 
combination with SNP for 72 h when compared 
with the untreated group (Table 1). Since sub-G1 
peaks include early and late apoptotic cells, but 
also a part of necrotic cells, such large sub-G1 
fractions provide strong evidence for cytotoxicity 
induced with 1400W and/or c-PTIO resulting in 
the decrease of the number of viable cells. 
Furthermore, the stage at which growth inhibition 
induced with 1400W and/or c-PTIO occurs in the 
A375 and SK mel-28 cell cycle progressions 
were determined, with cellular distribution in the 
different phases of the treatment (Table 1). 
Exposure of 1400W and/or c-PTIO resulted in a 
progressive and sustained accumulation of cells 
in the S and G2/M phases. Further, the 
percentage of S and G2/M phases cells 
increased, while those in the G1 phase 
decreased after treatment with 1400W and/or c-
PTIO (p < 0.05) (Table 1). 
 
Figure 2: Regulation of A375 and SK mel-28 cell growths by endogenous NO•. A375 cells were treated with NO• 
donor SNP (0-1000 μM) for 48 h, and cell viability was determined by MTT assay (A). A375 and SK mel-28 cells 
were treated with cisplatin (100 μM) alone or combined with 1400W (4 mM) or c-PTIO (400 μM) in the presence 
or absence of SNP for 48 h (B). Results are presented as a percentage of control cells (mean ± SD, n=3). *p < 
0.05 versus control; #p < 0.05 versus cisplatin; †p < 0.05 versus 1400W; ‡p < 0.05 versus c-PTIO 
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Figure 3: Apoptosis of A375 (A) and SK mel-28 (B) cells by 1400W (4 mM) or c-PTIO (400 μM) alone, or 
combination (4 mM of 1400W pre-incubated with 200 μM of c-PTIO for 24 h) in the presence or absence of 0.1 
μM SNP treatment. Induction of apoptosis in comparison to control cultures was evaluated after double staining 
with FITC-Annexin V and PI. In each dot plot, the percentage of Annexin V-positive, PI-negative (early apoptosis, 
lower right quadrant) and of Annexin V-positive, PI-positive cells (late apoptosis, upper right quadrant) is 
reported. Etoposide at 50 μM concentration was added to act as positive control. Values are mean ± SD (n=3). *p 
< 0.05 versus control; #p < 0.05 versus 1400W; †p < 0.05 versus c-PTIO; ‡p < 0.05 versus 1400 + c-PTIO 
 
Table 1: Cell cycle distribution by 1400W and/or c-PTIO in the presence or absence of SNP treated for 72 h in 
A375 and SK mel-28 cells 
 
Variable Apoptotic cells 
(sub-G1) 
Non-apoptotic cells 
G0/G1 S G2/M 
A375     
Untreated control 12.5 ± 0.11 62.6 ± 1.10 3.6 ± 0.17 21.4 ± 0.93 
4 mM 1400W 43.6 ± 1.71* 35.0 ± 1.36* 5.8 ± 0.33 14.2 ± 0.37* 
4 mM 1400W + 0.1 μM SNP 29.3 ± 1.08* 26.6 ± 1.05* 14.2 ± 0.37* 29.3 ± 1.17* 
400 μM c-PTIO 31.8 ± 2.14* 23.5 ± 0.30* 12.5 ± 0.16* 31.9 ± 2.00* 
400 μM c-PTIO + 0.1 μM SNP 32.9 ± 0.98* 22.3 ± 0.49* 13.1 ± 1.15* 31.5 ± 2.44* 
4 mM 1400W + 400 μM c-PTIO 42.7 ± 1.30* 27.7 ± 0.23* 7.7 ± 0.57* 21.8 ± 1.03 
4 mM 1400W pre-incubated with 200 
μM c-PTIO for 24 h    + 0.1 μM SNP 31.8 ± 2.52* 28.9 ± 0.13* 9.4 ± 0.81* 29.7 ± 1.34* 
SK mel-28     
Untreated control 14.0 ± 1.79 72.1 ± 1.20 5.1 ± 0.65 8.6 ± 1.26 
4 mM 1400W 25.7 ± 1.07* 44.8 ± 0.09* 12.8 ± 0.63* 15.6 ± 1.57* 
4 mM 1400W + 0.1 μM SNP 26.2 ± 1.05* 45.5 ± 1.12* 12.4 ± 0.74* 14.8 ± 0.42* 
400 μM c-PTIO 34.6 ± 1.82* 33.6 ± 0.51* 10.7 ± 0.23* 19.3 ± 0.92* 
400 μM c-PTIO + 0.1 μM SNP 30.5 ± 1.53* 35.0 ± 0.04* 11.5 ± 0.08* 21.1 ± 1.39* 
4 mM 1400W + 400 μM c-PTIO 30.2 ± 0.39* 32.2 ± 0.65* 12.7 ± 0.11* 23.7 ± 0.62* 
4 mM 1400W pre-incubated with 200 
μM c-PTIO for 24 h    + 0.1 μM SNP 26.0 ± 1.34
* 32.0 ± 0.43* 13.1 ± 0.40* 27.2 ± 1.34* 
 
Induction of internucleosomal DNA fragmen-
tation induced 
 
Since a major biochemical feature of apoptosis is 
fragmentation of the genomic DNA, we analyzed 
genomic DNA after treating the cells for 72 h. 
Treatments with 1400W and/or c-PTIO induced 
DNA ladder formation, confirming that apoptosis 
was a major contributor to cell death induced by 
these compounds (Figure 4). 
 
Expression of IAP family mRNA determined 
by semi-quantitative RT-PCR  
 
In this study, we subsequently investigated the 
mechanism underlying cell death induced by 
endogenous NO• depletion, with a focus upon 
antiapoptotic activity of IAP family member. We 
examined expression of survivin, cIAP1 and 
XIAP1 mRNA. Treatment of the cells with 1400W 
and/or c-PTIO for 72 h led to a reduction of 
survivin, cIAP1 and XIAP1 in both A375 and SK 
mel-28 cells (Figure 5). 
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Figure 4: Apoptotic DNA fragmentation in A375 and 
SK mel-28 cells. Cells following incubation with 1400W 
(4 mM) or c-PTIO (400 μM) alone, or combination (4 
mM of 1400W pre-incubated with 200 μM of c-PTIO 
for 24 h) treated for 72 h detected DNA fragment using 
agarose gel electrophoresis 
 
 
Figure 5: Expression of survivin, XIAP and cIAP1 
mRNA in A375 and SK mel-28 cells after treatment 
with 1400W (4 mM) or c-PTIO (400 μM) alone, or 
combination (4 mM of 1400W pre-incubated with 200 
μM of c-PTIO for 24 h). Semi-quantitative RT-PCR 
was performed using primer specific to survivin, XIAP 
and cIAP1 or β-actin control on 1 μg total RNA 




In recent years it has become evident that 
endogenous NO• has been associated with 
various other tumors including melanoma and 
high levels of tumor iNOS have been associated 
with tumor progression and poor survival, 
although the detailed molecular mechanisms 
involved are not clear [17]. Understanding the 
mechanisms involved in the modulation of 
endogenous NO• expression is important for the 
development of pharmacological strategies 
aimed to selectively alter the response of 
melanoma cells to various anticancer drugs. 
 
Data  presented  here  of  endogenous NO• was 
implicated in increased melanoma cell growth; 
cells treated with an iNOS inhibitor 1400W and 
NO• scavenger c-PTIO decreased the 
percentage of viable cells, confirming that 
endogenous NO• regulation accounts for 
melanoma cell proliferation. Little attention had 
been given to these and related questions until 
Ekmekcioglu et al showed recently, using in 20 
human metastatic melanoma tissue specimens 
[10], that iNOS and nitrotyrosine expression by 
the melanoma cells strongly correlated with poor 
survival in patients with stage 3 disease, 
suggesting a pathway whereby iNOS might 
contribute to enhanced tumor progression. Use 
of chemical NO• scavenger would nullify NO• 
stores by quickly reacting with any newly 
released NO•, whereas inhibition of NO• 
production by NOS does not deplete possible 
cellular NO• storage mechanisms [5]. 
 
The cell lines used in the present study displayed 
p53 function attributed in sensitivity to NO• 
modulators-induced cell death. In comparison to 
A375 (p53 wild-type) cells, SK mel-28 (p53 
mutant) cells were resistant to NO• modulators-
induced cell death (Figures 1B and C). The p53 
protein has broad range of biological functions, 
including regulation of the cell cycle, apoptosis, 
senescence, DNA metabolism, angiogenesis, 
cellular differentiation, and the immune response 
[18]. The key role of p53 as a tumor suppressor 
is to block cell cycle progression and/or to induce 
apoptosis, in response to cellular stresses such 
as DNA damage. However, mutant p53 has not 
only led to a loss of normal function of the wild-
type protein but also led to new abilities to 
promote cancer [19].  Mutant p53 is frequently 
associated with tumor progression, resistance to 
therapy, and poor prognosis [20].  
 
In the present study we report that the addition of 
0.1-100 μM SNP, a NO• donor, led to an increase 
in A375 cell growth but more than 100 μM SNP 
caused a dose-dependent decrease in cell 
viability. It suggests that low levels of NO• is 
involved in the maintenance of cell growth, 
whereas higher NO• concentrations lead to 
inhibition of growth, although the threshold 
between low and high levels of NO• is still 
dependent on the cell type and context within 
which NO• is found [6]. Similar results were 
observed in SK mel-28 melanoma cells (data not 
shown). In addition, we showed the 
chemoadjuvant potential of NO• modulators on 
cisplatin-mediated cell killing. Moreover, using 
SNP, cell growth returned to normal levels, 
confirming that NO• plays a role as a negative 
regulator of cisplatin-induced cytotoxicity. These 
results are in close agreement with earlier 
reported observations that NO• impairs the 
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apoptotic function of cells and increases their 
resistance to cisplatin-induced cell death in 
human cancer cells [21]. Cisplatin induces down-
regulation of Bcl-2 through proteasome 
emediated degradation. NO• negatively regulates 
this process through its ability to nitrosylate the 
protein and inhibit its ubiquitination. Because 
increased NO• production and Bcl-2 expression 
have been associated with several human 
tumors, NO• may be one of the key regulators of 
cell death resistance and tumor growth through 
S-nitrosylation [21]. 
 
The tumor suppressor p53 is activated by a 
variety of stress signals leading to either cell-
cycle arrest or apoptosis. As expected, inhibition 
of endogenous NO• induced p53-dependent 
apoptosis in human melanoma cells. It therefore 
was suggested that tumor-associated NO• 
production promotes cancer progression by 
providing a selective growth advantage of p53 
mutant cells. This hypothesis of a selective 
growth advantage of p53 mutant cells appears 
plausible because high concentrations of NO• 
and NO• metabolites, such as peroxynitrite or 
NO2-, cause DNA damage that in turn leads to 
p53-dependent apoptosis, but a sustained 
overproduction of NO• also is often associated 
with the initiation and progression of 
carcinogenesis [22]. Nevertheless, p53-
independent processes of NO•-mediated 
apoptosis have also been reported [23], 
suggesting that other genes than p53 might also 
play an important role in the NO•-dependent 
pathways. Our data indicate that NO• plays a role 
as a negative regulator of p53-dependent 
apoptosis in melanoma cells. DNA fragmentation 
suggested that 1400W and/or c-PTIO induced 
cell death, involved a mechanism of apoptosis, 
this hypothesis was confirmed by flow cytometric 
analysis. 
 
Since sub-G1 peaks include early and late 
apoptotic cells, but also a part of necrotic cells, 
such large sub-G1 fractions provide strong 
evidence for cytotoxicity induced with 1400W 
and/or c-PTIO resulting in the decrease of the 
number of viable cells. Furthermore, the stage at 
which growth inhibition induced by with 1400W 
and/or c-PTIO occurs in the A375 and SK mel-28 
cell cycle progressions were determined, with 
cellular distribution in the different phases of 
treatment. 1400W and/or c-PTIO promote cell 
growth inhibition by inducing S and G2/M phase 
arrests in human melanoma cells. 
 
Activation of the NF-κB transcription factor plays 
an important role in the inhibitory pathway 
against apoptosis [24]. The IAP family such as 
survivin, XIAP and cIAP1 is regulated 
transcriptionally by NF-κB [25]. These IAPs have 
been reported to directly bind and repress the 
activation of caspases such as caspase-3 and 
caspase-9, indicating that expression of IAPs 
under the control of NF-κB plays a pivotal role in 
the anti-apoptotic pathway [25]. Treatment of the 
cells with 1400W and/or c-PTIO for 72 h led to a 
reduction of survivin, cIAP1 and XIAP1 in both 
A375 and SK mel-28 cells, suggesting the high 
expression of these IAPs in human melanoma 
cells may act as a contributing factor to 
resistance by these two NO• modulators. 
However, our study provides some clues to 
elucidate the signaling pathways of the IAP 
genes because semi-quantitative RT-PCR can 
be highly variable and may not accurately reflect 
gene activity.  Further study will be required to 





The results of this study show that the depletion 
of endogenous NO• inhibits the growth of human 
melanoma by inducing cell cycle arrest and 
apoptosis via IAP inhibition, which acts as a 
protective factor against apoptosis in human 
melanoma cells. p53 wild-type A375 cells were 
shown to be more sensitive to apoptosis 
induction by NO• as compared to the p53 mutant 
SK mel-28 cells, suggesting that NO• is required 
for p53 activation. While these findings generally 
support the potential utility of these compounds 
as cancer chemopreventive or therapeutic 
agents, further research will be required to define 
more specifically the mechanisms through which 
they act. Recognition that NO• is a critical 
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